RETA

Reata Pharmaceuticals, Inc. Class A Common Stock
RETA

Overview Fund Activity
Delisted

RETA was delisted on the 25th of September, 2023.

Back to rankings

214 hedge funds and large institutions have $3.21B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
214
Holders Change
+9
Holders Change %
+4.39%
% of All Funds
3.37%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
43
Increased
73
Reduced
62
Closed
33
Calls
$92.8M
Puts
$73.6M
Net Calls
+$19.2M
Net Calls Change
-$92.3M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$132M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$84.4M
3
Citadel Advisors
Citadel Advisors
Florida
+$55M
4
Holocene Advisors
Holocene Advisors
New York
+$37M
5
Millennium Management
Millennium Management
New York
+$34.9M

Top Sellers

1
PA
Perceptive Advisors
New York
-$153M
2
DTC
Deep Track Capital
Connecticut
-$66.3M
3
Marshall Wace
Marshall Wace
United Kingdom
-$33.7M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$31.6M
5
SI
Sofinnova Investments
California
-$31.1M
Name Holding Trade Value Shares
Change 		Shares
Change %
Fidelity Investments
26
Fidelity Investments
Massachusetts
$31.1M +$18.4M +180,740 +145%
T. Rowe Price Associates
27
T. Rowe Price Associates
Maryland
$30.2M -$135K -1,324 -0.4%
Northern Trust
28
Northern Trust
Illinois
$29.4M +$522K +5,120 +2%
EMFAT
29
Emerald Mutual Fund Advisers Trust
Pennsylvania
$26M +$37.6K +369 +0.1%
MB
30
MPM BioImpact
Massachusetts
$23.9M +$5.87M +57,604 +33%
Goldman Sachs
31
Goldman Sachs
New York
$22.2M +$7.68M +75,344 +53%
Charles Schwab
32
Charles Schwab
California
$22M +$937K +9,187 +4%
Victory Capital Management
33
Victory Capital Management
Texas
$21.6M +$5.12M +50,249 +31%
JPMorgan Chase & Co
34
JPMorgan Chase & Co
New York
$21M +$8.46M +82,980 +67%
WP
35
Woodline Partners
California
$20.9M +$20.9M +205,108 New
BSA
36
Braun Stacey Associates
New York
$16.8M -$14.9M -146,235 -47%
Morgan Stanley
37
Morgan Stanley
New York
$16.6M -$8.17M -80,156 -33%
Norges Bank
38
Norges Bank
Norway
$14.8M -$2.03M -19,900 -12%
PHS
39
PFM Health Sciences
California
$14.8M +$14.8M +145,147 New
Bank of New York Mellon
40
Bank of New York Mellon
New York
$13.5M +$3.13M +30,668 +30%
AllianceBernstein
41
AllianceBernstein
Tennessee
$13.4M +$6.35M +62,262 +90%
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$12.9M +$841K +8,250 +7%
IHAM
43
Integral Health Asset Management
New York
$12.2M +$5M +49,000 +69%
SSA
44
Schonfeld Strategic Advisors
New York
$11.7M +$6.07M +59,557 +108%
Two Sigma Investments
45
Two Sigma Investments
New York
$11.1M -$1.58M -15,449 -12%
SCM
46
Suvretta Capital Management
New York
$11.1M +$9.56M +93,732 +621%
ABG
47
Ally Bridge Group
New York
$10.8M +$10.8M +105,558 New
FLSM
48
Frazier Life Sciences Management
California
$10.2M +$10.2M +100,430 New
SCM
49
Soleus Capital Management
Connecticut
$9.95M -$7.86M -77,045 -44%
TLP
50
Tri Locum Partners
New York
$9.82M +$2.96M +29,068 +43%
1
2
3 4 5